Neurologix Inc. (fka NRGXQ)

[Value_Investor]

The top six institutions alone hold 75.76% of OS based on the court papers and the SEC filings!
which imply an huge buy-out deal may kick in very soon...

Corriente Advisors LLC, 23%;
General Electric Pension Trust, 20.12%;
Palisades Private Partnership LP, 12.1%;
Medtronic, Inc., 7.3%;
DaimlerChrysler Corp. LLC Master Retirement Trust, 7.08%;
and ATEC Trust, 6.16%.

Note, the latest institution's ownership form was filed on 02/21/2013 which shows 2,036,171 shares are held by Medtronic, Inc.:

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125-13-069250.txt&FilePath=\2013\02\21\&CoName=NEUROLOGIX+INC%2FDE&FormType=SC+13D%2FA&RcvdDate=2%2F21%2F2013&pdf=


The OS is 27,997,701 shares in which only 12,570,000 shares float.

So all the individual investors together only hold less than 6,786,642 shares in which only a couple of millions of shares available for trading!

The biggest volume day in history was 03/19/2012: 1,631,747 shares traded at $0.002 ~ $0.018!
The second biggest volume day was 06/22/2007: 1,157,469 shares traded at $1.18 ~ $1.51!


The insiders ownership is 55.1%.

The business enterprise value is $2.62M or $0.0936 per share!

The cash value is $0.12 per share!


Note, this Bio-Tech's key patents etc. IP assets alone could worth millions of dollars!



Key technical updating: the 20/50/200-Day MAL is 0.0012/0.0010/0.0013.



Neurologix Inc. company stock, which is traded over the counter, closed on 03/16/2012 at $0.18. As recently as the summer of 2011, it traded around $0.8, now at the joke low $0.0015!

Note, the similar bio-tech Q stocks trade at 20 ~ 100 times higher MV now. So it is easy for 20-bagger rally from here!



Neurologix Inc. (NRGXQ) Business Description:

Neurologix, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders
(such as Parkinson disease) of the brain and Central Nervous System (CNS).

Neurologix, Inc., a development stage company, engages in the research and development of proprietary treatments for disorders of the brain and central nervous system primarily using gene therapies. Its treatments are designed as alternatives to conventional surgical and pharmacological treatments. The company primarily focuses on the development of a therapeutic product to meet the needs of patients suffering from Parkinson disease. Its core technology, NLX-P101, completed Phase II clinical trial of gene transfer for the treatment of advanced Parkinson disease. Neurologix also focuses on developing therapies to treat other neurodegenerative and metabolic disorders, including therapies relating to epilepsy, Huntington disease, and depression, as well as metabolic disorders, including genetically-based obesity.

The company was founded in 1999 and is headquartered in Fort Lee, New Jersey. On March 16, 2012, Neurologix, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Full Time Employees: 12

Website: http://www.neurologix.net/

Neurologix Inc.

One Bridge Plaza
Fort Lee, NJ 07024
United States - Map

Phone: [phone]

Fax: [phone]


Beware: the sticky post#909 contains lots of obsolete or 100% misinformation...